04.01.2022 • News

Invista Wins China Nylon Licensing Contract

Invista Textiles (UK), a division of US nylon giant Invista, has signed an agreement with China Resources Yantai Nylon to license technology for a new plant in China. The companies did not disclose a timeframe for the project.

Under the terms of the deal, Invista will supply its proprietary nylon 6,6 polymerization process for a facility located in the Economy & Technology Developing Zone in Yantai City, Shandong province. Invista said the line is the first since 2015 to license the technology.

“As with China Resources and all local partners, we look forward to working closely together for success on this new project and to identify additional opportunities for nylon 6,6 downstream applications, enabling strong growth as we contribute to the upgrading of the nylon 6,6 industry in China,” said Pete Brown, nylon polymer executive vice president, global intermediates, Invista.

Separately, Invista has taken over Flint Hills Resources’ propylene business with effect from Jan. 1. The transaction includes the plants in Houston and Longview, Texas. Ownership of the pipelines that supply these facilities will also transfer to Invista, but they will continue to be operated by Flint Hills Resources under contract.

“We’re excited for the opportunities that will be made possible by this integration of two of Koch Industries’ chemicals businesses,” said Invista chairman and CEO Jeff Gentry. “Flint Hills Resources’ propylene business complements Invista’s portfolio and will help us accelerate our vision of building a leading polymers and advanced materials company.”

Author: Dede Williams, Freelance Journalist

(c) Invista
(c) Invista

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.